stat6

STAT6-IN-2 (Comp R-84) is a STAT6 inhibitor that effectively reduces the secretion of the chemokine eotaxin-3, which induces eosinophil infiltration. This compound is valuable for studying immune diseases [1].

AS1517499 is a blood-brain barrier permeable inhibitor of STAT6 phosphorylation (IC50= 21 nM).

AS1810722, a fused bicyclic pyrimidine derivative, is an orally active and potent inhibitor of STAT6, demonstrating an IC50 of 1.9 nM. It exhibits effective inhibition of CYP3A4, positioning it as a promising candidate for research into allergic diseases, including asthma and atopic conditions.

STAT6-IN-5 (example 84) is an inhibitor of STAT6 (IC50 = 0.24 μM), applicable for investigating inflammation and allergies such as atopic dermatitis.

STAT6-IN-4 (compound 78) is a STAT6 inhibitor with an IC₅₀ of 0.34 μM, suitable for investigating inflammatory and allergic diseases.

STAT6-IN-7 (Compound 178) is a STAT6 inhibitor with an IC50 of 0.28 μM for inhibiting the binding of human STAT6/pIL-4Rα. It is utilized in research related to inflammation and allergic diseases.

STAT6-IN-1, a STAT6 inhibitor, exhibits high affinity for the SH2 domain of STAT6 (IC 50 = 0.028 µM), making it suitable for research on allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease, or cancer.

STAT6-IN-3 (Compound 18a) is an inhibitor of STAT6, targeting the Src Homology 2 (SH2) domain with an IC50 value of 44 nM. It is used in research on inflammatory disorders, such as asthma [1].

SD-436 is a selective and highly efficient STAT3 PROTAC degrader (DC50 = 0.5 μM), with an IC50 of 19 nM for STAT3, significantly higher than for STAT1/4/5/6. SD-436 depletes STAT3 and induces tumour regression in mouse leukaemia and lymphoma xenograft models.

YM-341619 (AS1617612) is a potent, orally active STAT6 inhibitor (IC50: 0.70 nM) that inhibits IL-4-induced Th2 differentiation in mouse splenic T cells with an IC50 value of 0.28 nM, without affecting Th1 cell differentiation. YM-341619 holds potential for research into allergic diseases, such as allergic asthma.

Febuxostat 67M-1 is an inhibitor of xanthine oxidase. It reduces uric acid production in the body and reduces the risk of gout or kidney stone formation.

Febuxostat 67M-4 is a derivative compound of Febuxostat 67M-1 which is an inhibitor of xanthine oxidase. It reduces uric acid production in the body and reduces the risk of gout or kidney stone formation.

Febuxostat 67M-2 is a derivative compound of Febuxostat 67M-1 which is an inhibitor of xanthine oxidase. It reduces uric acid production in the body and also used to reduce the risk of gout or kidney stone formation.

AK-1690 is a potent and selective STAT6 PROTAC degrader that induces degradation of STAT6 proteins in cells (DC50=1 nM) and depletes STAT6 proteins in mouse tissues, which can be used in cancer research.

IL-4 inhibitor is an inhibitor of IL-4.1It binds to IL-4 with a Kdvalue of 1.8 μM and inhibits IL-4 activity in a cell-based reporter assay (EC50= 1.81 μM). It is selective for IL-4 over IL-13 (EC50= 18.2 μM). IL-4 inhibitor inhibits IL-4-induced STAT6 phosphorylation in THP-1 monocytes (EC50= 3.1 μM), indicating inhibition of the IL-4-JAK1-STAT6 signaling pathway.

AK-068 is a STAT6 ligand with a Ki value of 6 nM, exhibiting at least 85-fold higher selectivity in binding to STAT6 over STAT5.

7-Bromohept-1-yne is a PROTAC Linker that can be used to synthesize AK-1690, a STAT6 (Signal transducer and activator of transcription 6) PROTAC degradator.

Smad2/3-IN-2 (Compound 3) is an inhibitor of the TGF-β-dependent Smad2/3 signaling pathway and the IL-4-dependent STAT6 signaling pathway, with IC50 values of 90 nM and 20 nM, respectively.

Smad2/3-IN-2 (Compound 27) is an inhibitor of the TGF-β-dependent Smad2/3 signaling pathway and the IL-4-dependent STAT6 signaling pathway, with IC50 values of 90 nM and 20 nM, respectively.

iHSP110-33 is an inhibitor of the molecular chaperone heat shock protein 110 (HSP110). This compound exhibits antitumor effects against large B-cell lymphoma and classical Hodgkin's lymphoma. It works synergistically with Selinexor, enhancing the inhibition of STAT6 phosphorylation and boosting its antitumor activity.

KT621 Analog 1 measured the DC50 value of STAT6 to be > 1 µM through the Meso Scale Discovery Assay (MSDA) method. This detection was obtained after culturing the human cell line A549 at 37°C for 24 hours.

KT621 Analog 2 also measured the DC50 value of STAT6 to be > 1 µM through the Meso Scale Discovery Assay (MSDA) method. This detection was derived after culturing the human cell line A549 at 37°C for 24 hours.

KT621 Analog 3 measured the DC50 value of STAT6 within the range of 0.1 - 1 µM through the Meso Scale Discovery Assay (MSDA) method. This detection was obtained after culturing the human cell line A549 at 37°C for 24 hours.

KT621 Analog 4 also measured the DC50 value of STAT6 to be > 1 µM through the Meso Scale Discovery Assay (MSDA) method. This detection was derived after culturing the human cell line A549 at 37°C for 24 hours.